Principal Securities’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.81M Sell
31,464
-2,904
-8% -$445K 0.07% 270
2025
Q4
$4.74M Sell
34,368
-1,403
-4% -$184K 0.07% 255
2025
Q3
$4.59M Sell
35,771
-913
-2% -$111K 0.08% 248
2025
Q2
$4.44M Buy
36,684
+7,814
+27% +$881K 0.08% 239
2025
Q1
$2.81M Buy
28,870
+113
+0.4% +$12K 0.06% 279
2024
Q4
$2.8M Buy
28,757
+2,613
+10% +$279K 0.06% 279
2024
Q3
$3.01M Buy
26,144
+4,153
+19% +$471K 0.07% 251
2024
Q2
$2.34M Buy
21,991
+5,630
+34% +$565K 0.06% 272
2024
Q1
$1.58M Sell
16,361
-3,788
-19% -$388K 0.05% 331
2023
Q4
$2.03M Buy
+20,149
New +$1.94M 0.08% 246

Other funds holding NVS

Principal Securities's NVS Position: Q1 2026 in Review

Principal Securities reduced its Novartis (NVS) stake by 8.4% in Q1 2026, selling an estimated $445K and leaving 31,464 shares worth $4.81M. The position accounts for 0.07% of the portfolio, ranked #270.

Principal Securities first reported a position in NVS in Q4 2023 and has held it in 10 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Principal Securities held 31,464 shares of Novartis worth $4.81M as of Q1 2026.
  • Principal Securities sold 2,904 Novartis shares in Q1 2026, an estimated $445K.
  • Novartis made up 0.07% of Principal Securities's portfolio in Q1 2026, its #270 holding.
  • Principal Securities first reported a position in Novartis in Q4 2023 and has held it in 10 quarters since.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Principal Securities's 13F filing for Q1 2026, filed 13 May 2026.